NCT04232748

Change in Body Weight During Treatment of Advanced Colorectal Cancer

Clinical Significance of Change in Body Weight During Treatment of Advanced Colorectal Cancer Patients - A Pilot Study

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 264 (estimated)
• Sponsor: Tuen Mun Hospital · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Colorectal cancer (CRC) is a significant and growing health burden in Hong Kong. According to data from Hong Kong Cancer Registry, CRC ranked the first in incidence and the second in mortality, with around 5,000 new cases diagnosed and more than 2,000 cancer-related mortality in 2014. The investigators aim to evaluate the association between serial weight change during first line treatment and outcomes in patients with metastatic CRC.

Detailed description

Studies have suggested that exposure to a greater number of chemotherapeutic agents is associated with better survival in metastatic colorectal cancer. Multiple factors might affect body weight during treatment. Cancer-related symptoms can impair quality of life and appetite. Cachexia syndrome affects around 50% of colon cancer patients and is characterized by cancer-induced catabolism with involuntary weight loss (fat and muscle), patients have increased lipolysis and change in skeletal muscle metabolism, including increased energy expenditure at rest and protein degradation, and decreased protein synthesis. Besides these disease factors, treatment related side effects are common causes of weight loss, such as inability to ingest or digest food effectively due to nausea, vomiting, and malaise. Based on these factors and the hypotheses between tumour control and weight gain, monitoring the serial weight change can have practical value.

Conditions

• Cancer, Colorectal
• Chemotherapy Effect
• Weight Loss
• Prognosis

Interventions

Type	Name	Description
DRUG	first line systemic treatment for colorectal cancer	systemic chemotherapy (capecitabine or fluorouracil, oxaliplatin or irinotecan, with or without biological agents including cetuximab, bevacizumab, or panitumumab.

Timeline

• Start date: 2019-01-01
• Primary completion: 2022-03-01
• Completion: 2022-03-01
• First posted: 2020-01-18
• Last updated: 2020-01-18

Locations

1 site across 1 country: Hong Kong